Adjunct therapies

Module 1: Rationale for adjunct therapies

Please log in to access the chapters in this module.
CME Credits: 0.5
Module duration: 0.5 hours
Launch date: Summer 2019 (version 1)
Updated: Spring 2023 (version 2)
Expiry date: March 2027
Audience: Diabetes and Metabolism Specialists (Subspeciality)

Note!
Forxiga (dapagliflozin) 5 mg no longer authorised for treatment of type 1 diabetes
Since this module was created, effective 25th October 2021 dapagliflozin 5 mg is no longer authorised for the treatment of patients with type 1 diabetes and should no longer be used in this population. This is based on AstraZeneca’s decision to remove the type 1 diabetes indication for dapagliflozin 5 mg.
The removal of the type 1 diabetes indication is not due to any safety concern for dapagliflozin in any indication, including type 1 diabetes.

This module explores the unmet need in treatment for type 1 diabetes, setting out the rationale for adjunct therapies.

Since 1922, we have had insulin as a treatment for type 1 diabetes. This module will now introduce you to why adjunct therapy might be important for treating patients with type 1 diabetes better. The learning objectives of this module are to understand the unmet needs of type 1 diabetes and also to understand how adjunct therapy works and why we’re thinking of doing that.
Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014 Nov 20;371(21):1972-82.
http://www.ncbi.nlm.nih.gov/pubmed/25409370

Learning Outcomes

By the end of this module, you will be able to:

✓ Explain the impact of type 1 diabetes on morbidity and mortality in adults

✓ Interpret clinical trial evidence investigating the benefits of adjunct therapy for adults with type 1 diabetes

✓ Identify treatment options for adults with type 1 diabetes


This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.


Contributors

Professor
Thomas Danne
Author
Professor
Chantal Mathieu
Expert Reviewer
Dr
Muhammad Fahad Arshad
Assessment Setter
Dr
Meera Ladwa
Assessment Setter